FAG
WST icon

Fortitude Advisory Group’s West Pharmaceutical WST Stock Holding History

Fortitude Advisory Group’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-106
Closed -$44K – 1311
2022
Q1 		$44K Hold
106
– – 0.02% 579
2021
Q4 		$49K Buy
+106
New +$45.6K 0.02% 556

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Fortitude Advisory Group's WST Position: Q2 2022 in Review

Fortitude Advisory Group sold out of West Pharmaceutical (WST) in Q2 2022, closing a stake of 106 shares — an estimated $44K sold.

Fortitude Advisory Group first reported a position in WST in Q4 2021 and held it in 2 quarters. The position peaked at $49K in Q4 2021. 655 funds tracked by Wall St. Rank hold WST as of Q2 2022.

  • Fortitude Advisory Group reported no remaining West Pharmaceutical position as of Q2 2022 after selling out during the quarter.
  • Fortitude Advisory Group sold 106 West Pharmaceutical shares in Q2 2022, an estimated $44K.
  • Fortitude Advisory Group first reported a position in West Pharmaceutical in Q4 2021 and held it in 2 quarters.
  • Fortitude Advisory Group's West Pharmaceutical position peaked at $49K in Q4 2021.
  • 655 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2022.

Based on Fortitude Advisory Group's 13F filing for Q2 2022, filed 16 Aug 2022.